GEFITINIB 250MG TABLET

Gefitinib 250mg Tablet is a prescription targeted therapy medicine designed for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. This oral anticancer medication is widely prescribed by oncologists as part of precision cancer care.

Gefitinib works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which plays a key role in cancer cell growth and proliferation. By blocking EGFR signaling, gefitinib helps slow tumor progression and improves treatment outcomes in patients with EGFR-positive NSCLC.

This oral targeted therapy is taken once daily as directed by a qualified oncologist. Gefitinib 250 mg Tablet is a prescription-only medicine that requires careful monitoring to ensure safe and effective cancer treatment. It is suitable for long-term use under strict medical supervision.

Product Features

• Targeted anticancer therapy tablet
• Contains Gefitinib 250 mg
• Used in EGFR-positive non-small cell lung cancer
• Oral tablet dosage form
• Helps inhibit cancer cell growth
• Manufactured under strict pharmaceutical quality standards
• Ensures consistent potency and effectiveness
• Prescription-required medication

How It Helps

• Blocks EGFR signaling to prevent cancer cell growth and division
• Slows tumor progression in EGFR-positive non-small cell lung cancer
• Supports targeted therapy by acting specifically on cancer cells
• Improves treatment outcomes under oncologist’s supervision